When the US Food and Drug Administration used the accelerated approval process to
authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD) …

The term “neurodegenerative diseases”(NDs) identifies a group of heterogeneous diseases
characterized by progressive loss of selectively vulnerable populations of neurons, which …

The neuroimmune system is a collection of immune cells, cytokines, and the glymphatic
system that plays a pivotal role in the pathogenesis and progression of Alzheimer's disease …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by the progressive
deterioration of cognitive functions. Due to the extended global life expectancy, the …

Although there are several genome-wide association studies available which highlight
genetic variants associated with Alzheimer's disease (AD), often the X chromosome is …

Microglia maintain brain homeostasis through their ability to survey and phagocytose
danger‐associated molecular patterns (DAMPs). In Alzheimer's disease (AD), microglial …

Epidemiological studies and clinical observations show evidence of sexual dimorphism in
brain responses to several neurological conditions. It is suggested that sex-related …

Alzheimer's disease (AD) is the most common neurodegenerative dementia with multi‐
layered complexity in its molecular etiology. Multiple omics‐based approaches, such as …

Research into Alzheimer's Disease (AD) describes a link between AD and the resident
immune cells of the brain, the microglia. Further, this suspected link is thought to have …

INTRODUCTION Existing blood‐based biomarkers for Alzheimer's disease (AD) mainly
focus on its pathological features. However, studies on blood‐based biomarkers associated …